Quick Answer
This guide helps assemble an assessable outsourced peptide work package: a measurable milestone, an eligible scope of work, a justified budget and supporting r…
What counts as non-dilutive funding for peptide R&evaluando proveedores especializadas síntesis peptídeos ma'bu̲ ya previsiones jár ta̲i, and which programs actually fit?
The fit rule is simple: match the program to the stage of evidence you can already demonstrate, not to the size of the check. The NIH Small Business Programs run in phases, nehmä NIH Grants Policy Statement’s SBIR/STTR section defines them: Phase I establishes the technical merit and feasibility of proposed research and the quality of the applicant’s performance, while Phase II continues that work and is funded on the results of Phase I plus the scientific and technical merit and commercial potential of the Phase II application. The same section lists a Direct to Phase II route for companies that have already demonstrated feasibility without holding a Phase I for that project, a sequential Phase IIB award, and the Commercialization Readiness Pilot for later-stage development.
State programs fill the gap below and beside the federal phases. ar Massachusetts Life Sciences Center’s Access and Accelerate grant awards typically $75,000 to $100,000 and may not exceed $150,000, releases 80% on execution and 20% on reimbursement, runs quarterly cycles, and may give priority to SBIR/STTR awardees without requiring an award. ar Life Sciences Center’s Impact Catalyst program provides up to $250,000 disbursed 25% / 25% / 50% against milestones, and it requires a Massachusetts base with more than 50% of employees in Massachusetts plus a seed round with committed investors. The residency and investor conditions are the reason a state grant is not the easier application; they are a different eligibility test.
|
Program |
Mechanism |
Ceiling |
Evidence stage required |
What it will not fund |
|---|---|---|---|---|
|
NIH SBIR/STTR Phase I |
Federal grant or contract |
$323,090 guideline (current NIH cycle) |
Feasibility and technical merit |
Development work beyond feasibility |
|
NIH SBIR/STTR Phase II |
Federal grant or contract |
$2,153,927 guideline (current NIH cycle) |
Completed Phase I results, wa demostrada viabilidad pa Direct ma Phase II |
Mpe̲fi fuera de ár ntsoni ngatho financiado |
|
Fabricante pruebas ar péptidos nthogi ne aceleración ar MLSC |
subvención estatal |
$150,000 máximo |
'be̲fi etapa temprana, ciclo trimestral |
Capital, ne hingi requiere 'nar premio SBIR yá STTR |
|
MLSC Impact Catalyst |
Subvención ar hito Dätatal |
$250,000 |
base Massachusetts, >50% empleados MA, comprometidos inversionistas semilla |
Empresas hinda nkohi ar residencia ne ar inversor |
Ya cifras NIH ya presupuestos directriz pa ar ciclo nu'bya, publicado en NIH s Fabricante pegilación peptídica 'nar nt'ot'ise̲ walkthrough ya fases SBIR ne STTR; institutos Nthuts'i ne centros xi da t'ot'e yá propios ntsoni , ne ar aviso activo nt'o̲t'e nt'ot'e ar financiamiento.
How do SBIR/STTR phase structure and work-share rules constrain how much peptide work I can outsource?
Nt'uni ar Hmunts'i peptídica Nmp Ár t'uni ar 'be̲fi compartido ge ar ndui restricción jar externalización síntesis péptidos pa 'yot'e financiados ya subvenciones, ne ar declara ndezu̲ yoho ya direcciones da significan xkagentho ar hmä. ar official SBIR program FAQ states that in Phase I the proposing firm must perform a minimum of two-thirds of the research or analytical effort, with one third subcontractable to another firm or research organization, and that in Phase II the firm must perform a minimum of one-half. NIH’s program page expresses the Phase I rule from the other end, as small businesses outsourcing 33% of Phase I research. Two-thirds performed and one-third outsourced are the same arithmetic.
For STTR, the small business and a single qualifying research institution must meet their respective minimum work shares under the applicable directive. The commonly cited 40% ne 30% minima leave at most 30% for others; they do not require a fixed 40/30/30 allocation. Confirm the agency’s effort calculation, eligible participants and active solicitation.
That measurement choice is the practical trap. If your solicitation measures effort in labor hours, a peptide synthesis invoice does not consume your outsourceable share the way you might assume; if it measures in total award dollars, every outsourced dollar counts against the fraction. Read the measurement sentence in your solicitation before you size the vendor scope.
How do I turn a scientific uncertainty into a milestone a review panel can verify?
Map the uncertainty to an achieved outcome with a number in it. NINDS’s published milestone examples are written as achieved outcomes, each tagged with a completion timeframe and carrying quantitative success criteria and go/no-go logic, rather than as activities to be performed. A milestone that reads “synthesize and characterize the modified peptide” describes work; a milestone that reads “obtain a lot with ≥95% HPLC purity and confirmed molecular mass by the end of month 6, with a go/no-go decision on scale-up” describes a result a reviewer can check against a document.
The phase definition tells you how far the milestone may reach. Because the NIH Grants Policy Statement’s SBIR/STTR section frames Phase I as establishing technical merit and feasibility, a Phase I milestone should prove that a difficult sequence can be made and measured, not that a manufacturing route is validated. Feasibility evidence is not development readiness, and no program publishes that rule in those words; the milestone form is the closest published expression of it.
Which outsourced peptide activities belong in which budget line, and what does each line justify?
The budget line follows the nature of the work, not the name of the vendor. NSF’s SBIR budget instructions place specialized work by non-employees in G.3 Consultant Services, subawards in G.5 when a significant portion of the work will be performed by another organization and the work is not widely commercially available, and the purchase of technical and R&D services from commercial sources in G.6 Other Direct Costs, naming analytical and testing services as a typical cost. The same instructions cap the consulting daily rate at $1,000 per eight-hour day, require a signed Letter of Commitment for consultants, and require subawards to carry a separate budget and justification in the same format as the main budget.
On the NIH side, the NIH SBIR/STTR application instructions state that F.5 covers all subaward and consortium organizations and other contractual costs, including both direct and indirect costs, and that contractual costs for support services such as laboratory testing of biological materials may warrant a categorical breakdown in Section L. NIH’s budget guidance for applicants adds that consultants belong in F.3 rather than in the senior/key personnel section unless they are employees of the applicant organization, and that each consortium requires its own budget form.
|
Scientific uncertainty |
Outsourced work package |
Budget line |
|---|---|---|
|
Difficult sequence, aggregation during synthesis |
Custom synthesis and purification |
NSF G.5 subaward, i Novabiochem Peptide Synthesis NIH F.5 contractual |
|
Multi-site modification or conjugation |
Modification and labeling work package |
NSF G.5 subaward, or NIH F.5 contractual |
|
Purity or identity claim for a milestone Peptides Manufacturer |
Analytical testing (HPLC, MS) |
NSF G.6 other direct costs, or NIH F.5 with a Section L breakdown |
|
Route design advice from a specialist |
Consultant services |
NSF G.3, or NIH F.3 Parallel Peptide Synthesizer |
Line numbers follow the agency forms and the active solicitation, so confirm them against the forms package you are actually submitting.
What documents will my peptide supplier actually issue, and which ones can a reviewer check?
A claim about a lot rests on that lot’s own certificate of analysis, chromatogram and mass-spectrometry data, and the reviewer checks the analytical method behind them. ICH Q2(R2), adopted November 2023, sets out in Table 1 which validation parameters each analytical purpose requires: identity requires specificity or selectivity only; a quantitative impurity (pureza) determination requires specificity, range, límite rango inferior (quantitation limit and detection limit), accuracy and precision; a limit test requires specificity and detection capability; and an assay for content or potency requires specificity, range, accuracy and precision. That table tells you which evidence to buy for the milestone you claimed. A purity milestone needs the full purity row; an identity confirmation milestone does not.
Electronic records carry their own requirements. 21 ' 11 applies to electronic records created, e, s, p, retrieved or transmitted under any agency records requirement, and to electronic records submitted to the agency under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, and it requires that computer systems, controls and attendant documentation be readily available for, and subject to, FDA inspection. For a peptide intended for a parenteral route, USP <85> is the harmonized bacterial endotoxins chapter, official since 1 Disyembre 2012, and it is the reference a reviewer will recognize for the endotoxin field. No regulator publishes a peptide certificate-of-analysis template, so the field list a reviewer expects is assembled from these anchors plus the supplier’s own method documentation.
Where must my readiness claims stop when describing planned versus demonstrated work?
The line sits between what a document in your application proves and what it promises. A feasibility lot with a certificate of analysis proves that a sequence was made and measured; it does not prove that the process is reproducible at another scale, and it does not prove that a later modification will work on the same scaffold. NINDS’s published milestone examples show the safe phrasing: each milestone states an achieved outcome with a completion timeframe and a go/no-go gate, which keeps the claim inside the period the work is funded for.
Where the evidence stops, say so in the application. No program publishes an explicit rule distinguishing “will demonstrate” from “has demonstrated” in a commercialization narrative, so the discipline has to come from the phase definitions and the milestone form rather than from a quoted regulation. If your only data is a single analytical run, describe it as a single analytical run and place the reproducibility question in the next milestone. Reviewers read overstated readiness as a risk, and the correction costs more than the caution.
How do I choose and brief a peptide partner so the analytical documentation holds up?
Brief the partner on the milestone, not on the sequence alone. A peptide modification and labeling work package brief should name the analytical purpose the milestone depends on, because ICH Q2(R2), adopted November 2023, ties the required validation parameters to that purpose, and a supplier who knows whether you need a purity determination or an identity confirmation will quote the right testing. The brief should also state the lot-level records you expect to receive, nxa 21 ' 11 governs the electronic records a supplier maintains and makes them subject to inspection.
Continuity across vendors is where documentation usually breaks. If synthesis, modification and analytical testing sit with three suppliers, the analytical method may not transfer, and the reviewer sees three method descriptions instead of one traceable chain. Coordinating synthesis, modification or labeling and analytical testing with one partner, or at minimum fixing the analytical method before the first lot is made, keeps the route from being duplicated and keeps the method identifier consistent across lots. Pide ar identificador ar nt'ot'e, columna, gradiente, wavelength and reference standard in the certificate, and confirm the mass-spectrometry ionisation mode, because those are the fields that let a reviewer reproduce the result.
Common mistakes to avoid
The most common mistake is treating the guideline budget figure as the operative one. ar NIGMS SBIR page states that NIGMS will not accept applications with budget requests exceeding the statutory budget limitation defined in the specific notice of funding opportunity’s hard cap, except where the project fits an SBA-approved waiver topic, and that applicants considering an over-cap budget should contact the NIGMS SBIR coordinator at least six weeks before the submission due date. The institute and the notice override the guideline.
Three others recur. Placing a synthesis invoice in the wrong line, hä NSF’s SBIR budget instructions put analytical and testing services in G.6 and subawards in G.5, invites a budget correction. Claiming a purity specification from a supplier’s general marketing page rather than from the lot’s own certificate is the fastest way to lose a reviewer’s confidence, because the specification belongs to the lot. And presenting FDA’s current Q1 stability page as settled guidance misreads its status: that page presents a June 2025 draft consolidated revision, docket FDA-2025-D-1106, marked not for implementation and containing non-binding recommendations, so a stability design should cite the guidance in force and note the consolidation draft separately.
resultados: what a fundable, verifiable work package looks like
An assessable package contains a justified milestone, eligible work allocation, supported budget and a plan for traceable evidence. For exploratory peptide work, analytical qualification can be phase-appropriate; a full commercial-release validation package is not automatically required solely because a grant supports the work.
Verify the package by reading it as a reviewer would. For each milestone, name the document that proves it. If a milestone has no document behind it, either the milestone is written as an activity and needs rewriting, or the evidence does not exist yet and the milestone belongs in a later phase. Nu'bu̲ gi 'nar especificación wa 'nar paquete ar 'be̲fi revisado kontra nuya criterios nu'bu ar envío, do revisión ge ar Xtí bi thogi xi.
Frequently asked questions
Can I stack a state grant on top of an SBIR or STTR award?
r, siempre ke yoho ya programas financien 'na'ño costos ne hingi prohíbe apoyo concurrente. Grant ar nthogi ne ar Accelerate Massachusetts Life Sciences Center xta ntheki prioritario ja ya galardonados SBIR yá STTR pe hingi requiere 'nar premio komongu 'mui nthe ar elegibilidad, nja'bu da 'nar nt'ot'e jar dätä hnini ar tsa̲ da 'ñehe ir nge ár nt'ot'ise̲. Compruebe ar lenguaje compartido costos ar programa Dähnini kontra ár justificación ar bojä federal nu'bu asumir xkagentho ar Nthuts'i ar línea ar tsa̲ da cobrar yoho ya 'nandi.
Temu̲ thogi nu'bu̲ ar límite duro ma instituto ar sienta por debajo de ar presupuesto ar directriz publicado?
Gem'bu̲ gobierna ndo'yo ar Instituto, hingi ar directriz. Página SBIR 'nar nt'ot'ise̲ ar NIGMS states that applications exceeding the hard cap named in the specific notice of funding opportunity are not accepted unless an SBA-approved waiver topic applies. NIGMS also asks applicants whose budget approaches the cap to contact program staff at least six weeks before the deadline, which is enough lead time to rescope a work package rather than discover the ceiling after submission.
Can my peptide supplier be the named research institution on an STTR?
Only if the supplier is a qualifying research institution and the split holds. The SBIR/STTR Policy Directive sets the STTR floor at 40% of R&D performed by the small business and 30% by a single partnering research institution, with third-party subcontracting capped at 30%. Deviations are not permitted because the requirement sits in statute at 15 USC 638(a), so a supplier that cannot carry the 30% role changes the structure of the award, not just the budget.
How long should I allow for outsourced analytical work inside a Phase I?
Plan the analytical package to finish well inside the award period. NIH’s own walkthrough of the SBIR and STTR phases describes Phase I periods of performance running from six months to two years, with the shorter end common. Síntesis, modification and characterization are sequential, so a late specification compresses the verification window rather than the science.
Njäts'i nu'bu
A coherent work package can be ready for review without being guaranteed funding. Scientific merit, eligibility, program priorities, budget availability and the active notice determine the decision. Tie each milestone to an appropriate evidence plan and cost justification.
The next step is a document audit: for every milestone in your draft, confirm that a certificate of analysis, chromatogram, mass spectrum or method record exists or is scheduled in the funded period. Where one is missing, either the milestone moves to a later phase or the evidence moves into the current one. That check can expose unsupported readiness claims before submission, which is a reviewer finding a readiness claim the documents do not support.
About the publisher. MOL Changes is a peptide research and development organisation that sells custom peptide synthesis, modification and production services, so it has a commercial interest in how outsourced peptide work is described. Pesar ár perspectiva ko nä'ä jar mente; ar guía 'be̲t'o hingi bi jagu̲ju̲ yá 'befi.
